Vir Biotechnology, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2023 Annual Meeting of Stockholders held by Vir Biotechnology, Inc. on May 19, 2023. The record date for the meeting was March 30, 2023, with 133,930,936 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on three proposals at the Annual Meeting:
- Proposal 1: Election of Directors - Stockholders elected four Class I Directors to serve until the 2026 Annual Meeting.
- Robert More: 109,608,096 votes for.
- Janet Napolitano: 98,720,333 votes for.
- Vicki Sato, Ph.D.: 98,355,146 votes for.
- Elliott Sigal, M.D., Ph.D.: 109,721,001 votes for.
- Proposal 2: Advisory Vote on Executive Compensation - Stockholders approved the compensation of named executive officers with 106,031,723 votes for and 4,377,092 votes against.
- Proposal 3: Ratification of Auditors - Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, with 118,688,387 votes for.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation of the four newly elected directors and their term expiration in 2026.
- Verification of the ratification of Ernst & Young LLP as the auditor for fiscal year 2023.
- Review of the specific vote counts for executive compensation to assess shareholder sentiment.
- Confirmation of the total number of shares outstanding (133,930,936) as of the March 30, 2023 record date.